Summary: Biotalys has announced a strategic refocus to prioritize its most advanced protein-based biofungicide programs, including EVOCA NG and BioFun-6. To streamline operations and extend its financial runway, the company is suspending early-stage activities and reducing its workforce by 30 employees. This restructuring is expected to reduce total cash burn by €20 million through the end of 2028 as the company prepares for the commercial launch of EVOCA NG.
Biotalys Announces Strategic Refocus to Prioritize Advanced Biofungicides and Streamline Operations
Ghent, BELGIUM — February 09, 2026
Biotalys (Euronext: BTLS), an AgTech company developing protein-based biocontrols for sustainable crop protection, today announced its intention to proceed with a strategic refocus. The initiative is designed to concentrate resources on its highest-priority programs and right-size its organizational structure.
As part of this transition, Biotalys intends to suspend its early-stage activities and reduce its workforce by 30 employees. This strategic shift is expected to result in an estimated reduction in total cash burn of €20 million until the end of 2028, versus the current operating structure. The company confirmed its cash runway extends into May 2026.
- Core Biofungicides: Resources will focus on progressing the most advanced programs: EVOCA NG and BioFun-6.
- EVOCA NG Commercialization: Following the EPA approval of first-generation EVOCA in December 2025, EVOCA NG is planned for a US launch in 2029 and Europe in 2030, targeting a $1.1 billion combined market.
- Strategic Partnerships: The company will continue to support partnered programs, including BioFun-7 (Gates Foundation), BioIns-2 (Syngenta), post-harvest solutions (AgroFresh), and manufacturing scaling (21st.BIO).
“It is imperative that we deploy capital where it creates the greatest impact,” said Kevin Helash, CEO of Biotalys. “A narrowing of the focus to our core assets and most advanced programs aims to strengthen our ability to deliver innovative, sustainable crop protection solutions to growers and, subject to securing additional funding, to advance our path to long-term value creation.”
Biotalys noted it is currently in discussions with investors regarding potential financing options to support this sharpened portfolio, aiming to significantly reduce the investment required to reach its goal of becoming a pioneer in Precision Biocontrols.
Leave a Reply